Nasdaq

BD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing

FRANKLIN LAKES, N.J. and OREM, Utah, Jan. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in ...
WGNO

BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test

FRANKLIN LAKES, N.J., Feb. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) ...
Nasdaq

BD Submits Pre-Market Approval Supplement to FDA to Enable ThinPrep® Pap Test™ PreservCyt® Solution to be Used with the BD Onclarity™ HPV Assay

FRANKLIN LAKES, N.J., Sept. 23, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market ...
Pharmabiz

BD introduces new liquid based cytology technique to enable accurate cervical cancer screening

BD Life Sciences-Diagnostic Systems, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced the launch of BD SurePath Direct to Slide. It is a liquid ...
News Medical

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) ...